What 62 Ventures does

62 Ventures is a Chicago-based, privately-held venture capital fund that invests in early-stage companies from pre-seed through Series C, writing checks of $1M to $10M and operating both as lead and co-investor. The fund is led by Glen Tullman as Principal and Founder, with stated focus on companies headquartered in the United States, India, and the Middle East, and on sectors including health and care, education, and environmental sustainability. Publicly disclosed portfolio companies are Khyaal (a senior citizen super-app in India), Loop Health (an India-based health insurance broker with an in-house medical team), and Transcarent-related exposure via equity participation in Transcarent's $621M acquisition of Accolade (announced January 8, 2025), co-invested with General Catalyst.

The firm does not develop or sell technology products; its operating model is investment-driven, with revenue mechanics typical of early-stage venture: equity participation in portfolio companies, future exits providing carried-interest economics, and management fees implied by fund structure (not disclosed). Distribution of capital is conducted through direct equity investment and syndicated co-investment, while deal sourcing leverages the personal network of Glen Tullman, who concurrently serves as CEO of Transcarent, Co-Founder & Managing Partner of 7wireVentures, and Co-Founder of Community Ventures. The team is small (1-10 employees), concentrated on a single principal, with public contact routing through [email protected].

The strategic positioning of 62 Ventures is best understood as one node within a broader Tullman-led venture platform that spans Transcarent (operating company), 7wireVentures (established Illinois VC fund), and Community Ventures. This structure gives 62 Ventures differentiated access to deal flow and follow-on capital, but also concentrates key-person risk on a single individual whose track record (Livongo's $18.5B merger with Teladoc, Allscripts IPO, Enterprise Systems sale) is the fund's primary intangible asset.

Name

62 Ventures

Legal name

62 Ventures

Website

https://62-ventures.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

62 Ventures is a Chicago-based early-stage venture capital fund led by Glen Tullman that invests $1M-$10M checks from pre-seed through Series C in health, education, and sustainability companies across the US, India, and the Middle East.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investors, Nec (6799)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital funding
• Early-stage investments
• Pre-seed to Series C
• Startup equity investing
• Growth capital

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Returns: 62 Ventures generates returns through equity investments in early-stage companies. The firm writes checks between $1M to $10M and invests from pre-seed through Series C stages, targeting companies in health and care, education, environmental sustainability, and other forward-thinking industries.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

62 Ventures is a Chicago-based venture capital fund that makes equity investments in early-stage companies from pre-seed through Series C stages. The firm typically writes checks between $1 million and $10 million per company, focusing on startups headquartered in the United States, India, and the Middle East that leverage technology to disrupt healthcare, education, and environmental sustainability industries.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-stage equity investments (pre-seed through Series C) Equity capital deployed into early-stage technology-driven companies headquartered in the United States, India, and the Middle East, with thematic focus on health and care, education, and environmental sustainability. The firm both leads and co-invests, targeting founders with social impact innovation, adaptability, and category-defining potential.

Quantifiable outcome

• Transcarent's acquisition of Accolade for $621M in cash, representing a 110% premium
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• KhyaalcoreStrategic or Co-development PartnerKhyaal is a portfolio company of 62 Ventures - a super-app for senior citizens in India where seniors can participate in educational sessions, make secure payments, and access curated products and services. This represents a strategic investment partnership in digital healthcare innovation for emerging markets.
• Loop HealthcoreStrategic or Co-development PartnerLoop Health is a portfolio company of 62 Ventures - a company on a mission to bring value and quality back to healthcare with an in-house medical team acting as family doctors. Loop is the first health insurance broker with an in-house medical team, bringing together primary care physicians, specialty networks, and health insurers under one roof.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Regional players

• Drive Capital: Mid-stage US VC with significant healthcare and Midwest focus; comparable sector overlap and similar geographic anchoring in the broader US market.

Direct peers

• Optum Ventures: Healthcare-focused venture arm of Optum/UnitedHealth Group investing in early- and growth-stage digital health companies; highly comparable sector focus to 62 Ventures' healthcare thesis.
• Flare Capital Partners: Healthcare-focused early-stage VC investing across digital health, services, and healthcare technology; closely comparable seed-to-Series B focus and sector specialization to 62 Ventures.
• 7wireVentures: Direct peer with shared founder (Glen Tullman) operating a consumer-focused digital health VC fund out of Chicago. Highly comparable investment thesis and geographic footprint to 62 Ventures.

Broad incumbents

• Bain Capital Ventures: Multi-stage VC actively investing in healthcare, fintech, and enterprise tech; comparable stage range and overlapping healthcare thesis to 62 Ventures.
• GV (Google Ventures): Generalist multi-stage VC with a substantial healthcare and life sciences portfolio; comparable sector breadth and stage coverage (seed through growth).
• Khosla Ventures: Pioneering sector-focused VC covering health, sustainability, education, and frontier tech from seed through growth stages; directly comparable stage range and sector breadth.
• Andreessen Horowitz (a16z): Large multi-stage VC with dedicated Bio/Health, Climate, and Education practices — comparable sector coverage and stage range from seed to growth.
• Sequoia Capital: Premier global multi-stage VC investing across healthcare, sustainability, and enterprise from seed to growth; comparable stage range and category coverage.
• General Catalyst: Large, established multi-stage VC with a deep healthcare practice that has co-invested directly with 62 Ventures on the Transcarent-Accolade transaction; comparable sector overlap (healthcare, sustainability).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 62 Ventures